Paper Details

  1. Home
  2. Paper Details

A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

Author: , ChoiSungku, Ho LeeJung, HongInja, Hoon OhByoung, JuYoung-Su, JungHan-Yong, Kil YeonByeong, Nam BaeJae, ParkJonghan, SuhGuk-Hee, Uk LeeChang, Yeon JungHee

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Galantamine hydrobromide, a dual acetylcholinesterase inhibitor and nicotinic receptor modulator, is being studied as a potential treatment for Alzheimer's disease (AD) in Korea, where the aging population and prevalence of AD are increasing.
Paper Details　
Original Abstract of the Article :
With the Korean population rapidly aging and the number of Koreans with Alzheimer's disease(AD) steadily growing, treatment of AD is becoming an increasing concern. Galantamine hydrobromide, a dual acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, is being studied in th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2004.10.006

データ提供：米国国立医学図書館（NLM）

Galantamine for Alzheimer's Disease: A Promising Treatment for Korean Population

This study investigates the use of galantamine, a medication for Alzheimer's disease, in a Korean population. The researchers conducted a double-blind, community-controlled trial comparing different doses of galantamine. The results suggest that galantamine can be an effective treatment option for mild to moderate Alzheimer's disease in the Korean population.

Galantamine's Potential in Alzheimer's Treatment

The study's findings provide evidence for the effectiveness of galantamine in treating Alzheimer's disease in the Korean population. It's important to note that the study focused on mild to moderate Alzheimer's disease, and further research is needed to assess its efficacy in more severe cases.

Living with Alzheimer's Disease: Dr. Camel's Advice

Imagine a camel navigating a vast desert - it needs to be patient and persistent in its journey. Similarly, living with Alzheimer's disease can be a challenging journey for both patients and their families. It's essential to seek support from healthcare professionals and support groups to navigate this complex condition.

Dr. Camel's Conclusion

This study provides valuable insights into the potential of galantamine as a treatment option for Alzheimer's disease in the Korean population. The research highlights the importance of understanding the specific needs of different populations when it comes to Alzheimer's disease. As Dr. Camel, I believe that research into this debilitating condition is crucial for finding effective treatments and improving the lives of those affected.

Date :
  1. Date Completed 2005-03-08
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

15598477

DOI: Digital Object Identifier

10.1016/j.clinthera.2004.10.006

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.